Drug Trial Radar · NCT00002970
506U78 in Treating Patients With Refractory Hematologic Cancer
Last checked: Nov 20, 2026Latest source record: Jul 2, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Jun 1997
Primary completion
Jan 2005
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- Children's Cancer Group
- First posted
- Aug 11, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Lymphoblastic Lymphoma
- T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
nelarabineDrug
Given IV
methotrexateDrug
Given IT
cytarabineDrug
Given IT
therapeutic hydrocortisoneDrug
Given IT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early marrow CR plus PR rate at day 21Time frame: Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Oncology Group
Arcadia, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.